MRONJ and Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®)

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

March 1, 2027

Conditions
Medication Related Osteonecrosis of the Jaw
Interventions
DEVICE

MRONJ resection plus PN+HA

Surgical management will be performed by reflecting a full-thick flap to expose the entire affected area, followed by removal of necrotic bone until a vital, unaffected bony margin will be obtained. After bone resection, the PN+HA (Regenfast®) will be applied on the residual bone surface. Wound management will be done via primary closure.

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06984107 - MRONJ and Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®) | Biotech Hunter | Biotech Hunter